ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3232

Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation

Maarten R. Hillen1,2, Sofie L.M. Blokland1,2, Elena Chouri1,2, Ana Lopes1,2, Aike A. Kruize2, Marzia Rossato1,2, Timothy R.D.J. Radstake1,2 and Joel A.G. van Roon1,2, 1Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: MicroRNA, Sjogren's syndrome and dendritic cells

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Sjögren's Syndrome II: Basic Insights

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:  Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and dryness of mouth and eyes. Type-1 classical dendritic cells (cDCs) are very potent antigen presenting cells known to induce strong T-cell proliferation and cytokine production. Despite the fact that especially cDC1s are candidate key players in the activation of local T and B-cells in pSS, they have rarely been studied in pSS. Considering the critical role of micro-RNAs (miRNAs) in regulation of gene expression, we investigated miRNA expression in isolated cDC1s of patients with pSS.

Methods:  Two independent cohorts (discovery and validation) were established, consisting of 29 pSS patients who were classified according to the 2002 criteria. 17 healthy controls (HC) were included as control group. cD1c+ CD19- cells were isolated from peripheral blood using MACS and we performed miRNA profiling of 758 miRNA targets using the OpenArray platform in the donors included in the discovery cohort. A selection of 15 miRNAs found to be differentially expressed in the pSS group versus the control group (at p<0.05, with at least a difference between the groups of log2) was measured in the independent validation cohort using a custom made array. We performed pathway enrichment with the experimentally supported targets of the validated miRNAs to assess their function in these cells.

Results:  A total of 24 miRNAs were downregulated in pSS patients versus HC in the discovery cohort. Of these, 16 targets were selected for validation. Pathway enrichment showed that the experimentally supported targets of these miRNAs are mainly involved in growth-factor signalling and vesicle trafficking (p<0.05, FDR corrected). We are currently performing functional experiments in primary cells to dissect the effects of the dysregulated miRNA expression in these cells.

Conclusion:  miR-130a and miR708 are significantly downregulated in cDC1s of patients with pSS, which indicates dysregulation in a range of pathways that are involved in DC function. These are the first data from primary cells to indicate dysregulation of type-1 cDCs in this group of patients, urging for further assessment of these cells in future studies.


Disclosure: M. R. Hillen, None; S. L. M. Blokland, None; E. Chouri, None; A. Lopes, None; A. A. Kruize, None; M. Rossato, None; T. R. D. J. Radstake, None; J. A. G. van Roon, None.

To cite this abstract in AMA style:

Hillen MR, Blokland SLM, Chouri E, Lopes A, Kruize AA, Rossato M, Radstake TRDJ, van Roon JAG. Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/decreased-expression-of-micro-rna-130a-and-micro-rna-708-in-type-1-classical-dendritic-cells-of-patients-with-primary-ss-indicates-their-dysregulation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-expression-of-micro-rna-130a-and-micro-rna-708-in-type-1-classical-dendritic-cells-of-patients-with-primary-ss-indicates-their-dysregulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology